Conrad Fischer describes sotatercept as a disease-modifying fusion protein that reduces pulmonary vascular resistance, reflecting growing attention to new mechanisms in pulmonary arterial hypertension treatment.
Sotatercept
*Fusion protein (ActRIIA-Fc)
*Disease-modifying agent, reducing pulmonary vascular resistance
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new expert voices, debates, and emerging ideas.
← Back to Healthcare